Drug Trial Radar · NCT00348764
ESGVS: Sclerotherapy With Lauromacrogol
Last checked: Nov 20, 2026Latest source record: Jul 6, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Mar 2004
Primary completion
Not stated
Study completion Dec 2006
Sponsor
- Lead sponsor
- University Hospital, GrenobleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and the tolerance of echoguided sclerotherapy using Lauromacrogol 400 foam for the treatment of Great Saphenous Vein (GSV) insufficiency. A comparative study of 3% versus 1% Lauromacrogol 400 foam.
Conditions
- Venous Insufficiency
- Saphenous Vein
Interventions
lauromacrogolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Removal of truncular GSV incompetence evaluated at 6 months by echo doppler: no persistence of "sus gonal" saphenous reflux > 1 second.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center of Vascular Medecine - 7 rue Lesdiguières
Grenoble, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.